<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02400905</url>
  </required_header>
  <id_info>
    <org_study_id>CID-100</org_study_id>
    <nct_id>NCT02400905</nct_id>
  </id_info>
  <brief_title>Evaluation of Safety and Effectiveness of the BioMimics 3D Stent System</brief_title>
  <acronym>MIMICS-2</acronym>
  <official_title>MIMICS-2: Evaluation of Safety and Effectiveness of the BioMimics 3D Stent System in the Femoropopliteal Arteries of Patients With Symptomatic Peripheral Arterial Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Veryan Medical Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ClinLogix. LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yale Cardiovascular Research Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Veryan Medical Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate that the BioMimics 3D Stent System meets the performance goals defined by VIVA&#xD;
      Physicians, Inc. for the safety and effectiveness of Nitinol stents used in the treatment of&#xD;
      symptomatic disease of the femoropopliteal artery. It is a prospective, single-arm,&#xD;
      multicenter clinical trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The BioMimics 3D stent is intended to improve luminal diameter in the treatment of&#xD;
      symptomatic de-novo, obstructive or occlusive lesions in native femoropopliteal arteries with&#xD;
      reference vessel diameters ranging from 4.0 - 6.0 mm. Subjects with symptomatic&#xD;
      atherosclerotic disease of the femoropopliteal artery who comply with all study eligibility&#xD;
      criteria may be considered for enrollment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 29, 2015</start_date>
  <completion_date type="Actual">December 3, 2019</completion_date>
  <primary_completion_date type="Actual">November 3, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Safety Endpoint (Freedom From a Composite of Major Adverse Events (MAE)</measure>
    <time_frame>30 days</time_frame>
    <description>Freedom from a composite of major adverse events (MAE) comprising death, any major amputation performed on the target limb or clinically-driven target lesion revascularization (TLR) through 30 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Effectiveness Endpoint (Primary Stent Patency Rate)</measure>
    <time_frame>12 months</time_frame>
    <description>The primary effectiveness endpoint of the MIMICS-2 Study was defined as the primary stent patency rate at 12 months. Patency was defined as no significant reduction in luminal diameter (&lt; 50% diameter stenosis) since the index procedure. Loss of patency was determined by an independent core laboratory when the peak systolic velocity ratio (PSVR) exceeds 2.0, or where angiography revealed &gt; 50% diameter stenosis, or where the subject had a CDTLR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Safety (Overall MAE Rate at 30 Days)</measure>
    <time_frame>30 Days</time_frame>
    <description>Contribution of individual MAE rates for death, major amputation performed on the target limb and clinically-driven target lesion revascularization to the overall MAE rate at 30 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long Term Safety (Overall MAE Rate at Month 12)</measure>
    <time_frame>12 months</time_frame>
    <description>Overall MAE rate at Month 12 and contribution of individual event rates to the overall MAE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious Adverse Events</measure>
    <time_frame>36 Months</time_frame>
    <description>Overall rate and incidence of type of serious adverse events from Day 0 through completion of Study follow-up at Month 36.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical Success</measure>
    <time_frame>Procedural (at end of index procedure)</time_frame>
    <description>Percentage of subjects in which a final result of ≤50% residual diameter stenosis (in-stent) was achieved at index procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary Stent Patency</measure>
    <time_frame>Months 12 &amp; 24</time_frame>
    <description>Determined at Months-12 and 24 using values of: PSVR &gt;2.0, &gt;2.4; &gt;2.5; and &gt;3.5, each to indicate loss of patency on duplex ultrasound or where angiography reveals &gt;50% diameter stenosis or where the subject undergoes clinically-driven TLR.&#xD;
Further analysis of the patency data purely using a reference PSVR of &gt;2.4, &gt;2.5 and &gt;3.5 was not feasible from the data that was collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Improvement of Rutherford Clinical Category by 1 or More</measure>
    <time_frame>Baseline, Day 30, Months 12 &amp; 24</time_frame>
    <description>Comparison of Rutherford Clinical Category measured at Baseline, Day 30, Months 12 and 24.&#xD;
Categories 0 - Asymptomatic&#xD;
- Mild claudication&#xD;
- Moderate claudication&#xD;
- Severe claudication&#xD;
- Ischemic rest pain&#xD;
- Minor tissue loss&#xD;
- Major tissue loss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Outcome (Six-Minute Walk Test)</measure>
    <time_frame>Baseline, Day 30, Months 12 &amp; 24</time_frame>
    <description>Comparison of measured at Baseline, Day 30, Months 12 and 24 (subgroup of US investigational sites only).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Outcome (Ankle Brachial Index (ABI) Measurement)</measure>
    <time_frame>Baseline, Day 30, Months 12 &amp; 24</time_frame>
    <description>Comparison of the ankle brachial index (ABI) measurement at Baseline, within 30 days after index procedure, then at Months 12 and 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Walking Impairment Questionnaire Score</measure>
    <time_frame>Baseline, Day 30, Months 12 &amp; 24</time_frame>
    <description>Comparison of the Walking Impairment Questionnaire at Baseline, within 30 days after index procedure, then at Months 12 and 24.&#xD;
The WIQ consists of 3 primary categories assessing walking distance, stair-climbing, and walking speed, as previously described. Individuals are asked to rate the degree of difficulty of various activities with responses ranging from 0 (unable) to 4 (none).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Freedom From Stent Fracture</measure>
    <time_frame>Months 12, 24 &amp; 36</time_frame>
    <description>Stent integrity measured as freedom from fracture, defined as clear interruption of a stent strut observed in a minimum of two projections, determined by core lab examination of X-rays taken with the leg in extension at 12, 24 and 36 Months.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">271</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>BioMimics 3D Vascular Stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implantation of BioMimics 3D nitinol stent using the BioMimics 3D Vascular Stent System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BioMimics 3D Vascular Stent System</intervention_name>
    <description>Femoropopliteal stenting</description>
    <arm_group_label>BioMimics 3D Vascular Stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Symptomatic peripheral arterial disease (PAD) of the lower extremities requiring&#xD;
             intervention to relieve de novo obstruction or occlusion of the native femoropopliteal&#xD;
             artery.&#xD;
&#xD;
          -  PAD classified as Rutherford clinical category 2, 3 or 4.&#xD;
&#xD;
          -  Resting ankle-brachial index (ABI) of ≤0.90 (or ≤0.75 after exercise of the target&#xD;
             limb) or angiographic or DUS evidence of &gt;/= 60%.&#xD;
&#xD;
          -  Single or multiple stenotic or occlusive lesions within the native femoropopliteal&#xD;
             artery (&quot;target lesions&quot;) that can be crossed with a guidewire and fully dilated.&#xD;
&#xD;
          -  Single or multiple target lesions must be covered by a single stent or two overlapping&#xD;
             stents.&#xD;
&#xD;
          -  Target lesion(s) eligible for treatment at least 1 cm distal to the origin of the deep&#xD;
             femoral artery and at least 3 cm above the bottom of the femur.&#xD;
&#xD;
          -  Target lesion(s) reference vessel diameter is between 4.0 mm and 6.0 mm.&#xD;
&#xD;
          -  Single or multiple target lesions measure ≥40 mm to ≤140 mm in overall length, with&#xD;
             ≥60% diameter stenosis by operator's visual estimate.&#xD;
&#xD;
          -  Patent popliteal artery (no stenosis ≥50%) distal to the treated segment.&#xD;
&#xD;
          -  At least one patent infrapopliteal vessel (&lt;50% stenosis) with run-off to the ankle.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Iliac stent in target limb that has required re-intervention within 12 months prior to&#xD;
             index.&#xD;
&#xD;
          -  Target vessel that has been treated with bypass surgery.&#xD;
&#xD;
          -  PAD classified as Rutherford clinical category 0, 1, 5 or 6.&#xD;
&#xD;
          -  Known coagulopathy or has bleeding diatheses, thrombocytopenia with platelet count&#xD;
             less than 100,000/microliter or INR &gt;1.8.&#xD;
&#xD;
          -  Stroke diagnosis within 3 months prior to enrollment.&#xD;
&#xD;
          -  History of unstable angina or myocardial infarction within 60 days prior to&#xD;
             enrollment.&#xD;
&#xD;
          -  Thrombolysis within 72 hours prior to the index procedure.&#xD;
&#xD;
          -  Acute or chronic renal disease (e.g., as measured by a serum creatinine of &gt;2.5 mg/dL&#xD;
             or &gt;220 umol/L), or on peritoneal or hemodialysis.&#xD;
&#xD;
          -  Significant disease or obstruction (≥50%) of the inflow tract that has not been&#xD;
             successfully treated at the time of the index procedure (success measured as ≤30%&#xD;
             residual stenosis, without complication).&#xD;
&#xD;
          -  No patent (≥50% stenosis) outflow vessel providing run-off to the ankle.&#xD;
&#xD;
          -  Target lesion(s) requires percutaneous interventional treatment, beyond standard&#xD;
             balloon angioplasty alone, prior to placement of the study stent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy M. Sullivan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Minneapolis Heart Institute / Abbott Northwestern Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Zeller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herz-Zentrum University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Masato Nakamura, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Toho University Ohashi Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brookwood Medical Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology Associates of Mobile</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36532</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Heart Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bradenton Cardiology Center</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MediQuest Research Group/ Munroe Regional Medical Center</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Vascular</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OSF St. Francis Medical Center</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prairie Education and Research Cooperative</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kings Daughters Medical Center</name>
      <address>
        <city>Ashland</city>
        <state>Kentucky</state>
        <zip>41101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endovascular Technologies / Grace Research</name>
      <address>
        <city>Bossier City</city>
        <state>Louisiana</state>
        <zip>71111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Institute of the South</name>
      <address>
        <city>Houma</city>
        <state>Louisiana</state>
        <zip>70360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Institute of the South</name>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <zip>70503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Outpatient Vascular Institute</name>
      <address>
        <city>Dearborn</city>
        <state>Michigan</state>
        <zip>48126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John Hospital &amp; Medical Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Vascular Center</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis Heart</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deborah Heart &amp; Lung Center</name>
      <address>
        <city>Browns Mills</city>
        <state>New Jersey</state>
        <zip>08015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NC Heart &amp; Vascular Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WakeMed Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riverside Methodist Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doylestown Hospital</name>
      <address>
        <city>Doylestown</city>
        <state>Pennsylvania</state>
        <zip>18901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pinnacle Health Harrisburg</name>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <zip>17043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Berks Cardiologists</name>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <zip>19610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Central Heart</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kore Cardiovascular Research</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Heart Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Specialist of TX / North Austin Medical Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78758</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grace Research</name>
      <address>
        <city>Huntsville</city>
        <state>Texas</state>
        <zip>77340</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mission Research Institute/Guadalupe Regional Medical Center</name>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <zip>78130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Associates of East Texas</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinen-Hospital</name>
      <address>
        <city>Arnsberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaets-Herzzentrum Freiburg-Bad Krozingen</name>
      <address>
        <city>Bad Krozingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diakonissenkrankenhaus Flensburg</name>
      <address>
        <city>Flensburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westküstenklinikum Heide</name>
      <address>
        <city>Heide</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig AoR Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Bonifatius Hospital</name>
      <address>
        <city>Lingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansai Rosai Hospital</name>
      <address>
        <city>Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kasukabe Chuo General Hospital</name>
      <address>
        <city>Kasukabe</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kokura Memorial Hospital</name>
      <address>
        <city>Kitakyushu-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morinomiya Hospital</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omihachiman Community Medical Center</name>
      <address>
        <city>Shiga</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toho University Ohashi Medical Center</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Japan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 23, 2015</study_first_submitted>
  <study_first_submitted_qc>March 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2015</study_first_posted>
  <results_first_submitted>November 5, 2018</results_first_submitted>
  <results_first_submitted_qc>December 21, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 18, 2019</results_first_posted>
  <last_update_submitted>May 11, 2021</last_update_submitted>
  <last_update_submitted_qc>May 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PAD</keyword>
  <keyword>PVD</keyword>
  <keyword>SFA stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 20, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/05/NCT02400905/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 25, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/05/NCT02400905/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>BioMimics 3D Stent</title>
          <description>Implantation of BioMimics 3D nitinol stent using the BioMimics 3D Stent System</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="271"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>30-Days Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="268"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>12-Months Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="256"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>24-Months Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="225"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>36 Months-Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="208"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="208"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>BioMimics 3D Stent</title>
          <description>Implantation of BioMimics 3D nitinol stent using the BioMimics 3D Stent System</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="271"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.4" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="253"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="215"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Primary Safety Endpoint (Freedom From a Composite of Major Adverse Events (MAE)</title>
        <description>Freedom from a composite of major adverse events (MAE) comprising death, any major amputation performed on the target limb or clinically-driven target lesion revascularization (TLR) through 30 days.</description>
        <time_frame>30 days</time_frame>
        <population>Subjects with available 30 day follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>BioMimics 3D Stent</title>
            <description>Implantation of BioMimics 3D nitinol stent using the BioMimics 3D Stent System</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Safety Endpoint (Freedom From a Composite of Major Adverse Events (MAE)</title>
          <description>Freedom from a composite of major adverse events (MAE) comprising death, any major amputation performed on the target limb or clinically-driven target lesion revascularization (TLR) through 30 days.</description>
          <population>Subjects with available 30 day follow-up</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="269"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Primary Effectiveness Endpoint (Primary Stent Patency Rate)</title>
        <description>The primary effectiveness endpoint of the MIMICS-2 Study was defined as the primary stent patency rate at 12 months. Patency was defined as no significant reduction in luminal diameter (&lt; 50% diameter stenosis) since the index procedure. Loss of patency was determined by an independent core laboratory when the peak systolic velocity ratio (PSVR) exceeds 2.0, or where angiography revealed &gt; 50% diameter stenosis, or where the subject had a CDTLR.</description>
        <time_frame>12 months</time_frame>
        <population>Subjects were included in analysis population if they had imaging data qualifying as a 12m visit and/or subjects without imaging data who experienced a CDTLR through 12 months. Additionally, if a subject is missing stent patency status at the 12m window but found to be patent at a later out-of-window date, subject was considered patent at 12 months</population>
        <group_list>
          <group group_id="O1">
            <title>BioMimics 3D Stent</title>
            <description>Implantation of BioMimics 3D nitinol stent using the BioMimics 3D Stent System</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Effectiveness Endpoint (Primary Stent Patency Rate)</title>
          <description>The primary effectiveness endpoint of the MIMICS-2 Study was defined as the primary stent patency rate at 12 months. Patency was defined as no significant reduction in luminal diameter (&lt; 50% diameter stenosis) since the index procedure. Loss of patency was determined by an independent core laboratory when the peak systolic velocity ratio (PSVR) exceeds 2.0, or where angiography revealed &gt; 50% diameter stenosis, or where the subject had a CDTLR.</description>
          <population>Subjects were included in analysis population if they had imaging data qualifying as a 12m visit and/or subjects without imaging data who experienced a CDTLR through 12 months. Additionally, if a subject is missing stent patency status at the 12m window but found to be patent at a later out-of-window date, subject was considered patent at 12 months</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Safety (Overall MAE Rate at 30 Days)</title>
        <description>Contribution of individual MAE rates for death, major amputation performed on the target limb and clinically-driven target lesion revascularization to the overall MAE rate at 30 days.</description>
        <time_frame>30 Days</time_frame>
        <population>Subjects with available 30 day follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>BioMimics 3D Stent</title>
            <description>Implantation of BioMimics 3D nitinol stent using the BioMimics 3D Stent System</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Safety (Overall MAE Rate at 30 Days)</title>
          <description>Contribution of individual MAE rates for death, major amputation performed on the target limb and clinically-driven target lesion revascularization to the overall MAE rate at 30 days.</description>
          <population>Subjects with available 30 day follow-up</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="269"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Freedom from Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Freedom from Major Amputation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Freedom from CD-TLR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Long Term Safety (Overall MAE Rate at Month 12)</title>
        <description>Overall MAE rate at Month 12 and contribution of individual event rates to the overall MAE.</description>
        <time_frame>12 months</time_frame>
        <population>Subjects are included in the analysis population if (i) they have sufficient follow-up (at least 12 months less 30 days), or (ii) they have had the event of interest (each event is considered separately).</population>
        <group_list>
          <group group_id="O1">
            <title>BioMimics 3D Stent</title>
            <description>Implantation of BioMimics 3D nitinol stent using the BioMimics 3D Stent System</description>
          </group>
        </group_list>
        <measure>
          <title>Long Term Safety (Overall MAE Rate at Month 12)</title>
          <description>Overall MAE rate at Month 12 and contribution of individual event rates to the overall MAE.</description>
          <population>Subjects are included in the analysis population if (i) they have sufficient follow-up (at least 12 months less 30 days), or (ii) they have had the event of interest (each event is considered separately).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Freedom from MAE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="261"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Freedom from Death</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="260"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Freedom from Major Amputation</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="258"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Freedom from CD-TLR</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="259"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious Adverse Events</title>
        <description>Overall rate and incidence of type of serious adverse events from Day 0 through completion of Study follow-up at Month 36.</description>
        <time_frame>36 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BioMimics 3D Stent</title>
            <description>Implantation of BioMimics 3D nitinol stent using the BioMimics 3D Stent System</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Adverse Events</title>
          <description>Overall rate and incidence of type of serious adverse events from Day 0 through completion of Study follow-up at Month 36.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>total number of participants</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All SAE (In-hospital)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All SAE (30 Days)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All SAE (12 Months)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All SAE (24 Months)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All SAE (36 Months)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Technical Success</title>
        <description>Percentage of subjects in which a final result of ≤50% residual diameter stenosis (in-stent) was achieved at index procedure</description>
        <time_frame>Procedural (at end of index procedure)</time_frame>
        <population>Subjects with available baseline angiography</population>
        <group_list>
          <group group_id="O1">
            <title>BioMimics 3D Stent</title>
            <description>Implantation of BioMimics 3D nitinol stent using the BioMimics 3D Stent System</description>
          </group>
        </group_list>
        <measure>
          <title>Technical Success</title>
          <description>Percentage of subjects in which a final result of ≤50% residual diameter stenosis (in-stent) was achieved at index procedure</description>
          <population>Subjects with available baseline angiography</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="269"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Primary Stent Patency</title>
        <description>Determined at Months-12 and 24 using values of: PSVR &gt;2.0, &gt;2.4; &gt;2.5; and &gt;3.5, each to indicate loss of patency on duplex ultrasound or where angiography reveals &gt;50% diameter stenosis or where the subject undergoes clinically-driven TLR.&#xD;
Further analysis of the patency data purely using a reference PSVR of &gt;2.4, &gt;2.5 and &gt;3.5 was not feasible from the data that was collected.</description>
        <time_frame>Months 12 &amp; 24</time_frame>
        <population>Relevant data was not collected to provide the outcome analysis</population>
        <group_list>
          <group group_id="O1">
            <title>BioMimics 3D Stent</title>
            <description>Implantation of BioMimics 3D nitinol stent using the BioMimics 3D Stent System&#xD;
BioMimics 3D Stent System: Femoropopliteal stenting</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Stent Patency</title>
          <description>Determined at Months-12 and 24 using values of: PSVR &gt;2.0, &gt;2.4; &gt;2.5; and &gt;3.5, each to indicate loss of patency on duplex ultrasound or where angiography reveals &gt;50% diameter stenosis or where the subject undergoes clinically-driven TLR.&#xD;
Further analysis of the patency data purely using a reference PSVR of &gt;2.4, &gt;2.5 and &gt;3.5 was not feasible from the data that was collected.</description>
          <population>Relevant data was not collected to provide the outcome analysis</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Improvement of Rutherford Clinical Category by 1 or More</title>
        <description>Comparison of Rutherford Clinical Category measured at Baseline, Day 30, Months 12 and 24.&#xD;
Categories 0 - Asymptomatic&#xD;
- Mild claudication&#xD;
- Moderate claudication&#xD;
- Severe claudication&#xD;
- Ischemic rest pain&#xD;
- Minor tissue loss&#xD;
- Major tissue loss</description>
        <time_frame>Baseline, Day 30, Months 12 &amp; 24</time_frame>
        <population>Number of participants participating in the study changed at 30 Days, 12 Months and 24 Months</population>
        <group_list>
          <group group_id="O1">
            <title>BioMimics 3D Stent</title>
            <description>Implantation of BioMimics 3D nitinol stent using the BioMimics 3D Stent System&#xD;
BioMimics 3D Stent System: Femoropopliteal stenting</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Improvement of Rutherford Clinical Category by 1 or More</title>
          <description>Comparison of Rutherford Clinical Category measured at Baseline, Day 30, Months 12 and 24.&#xD;
Categories 0 - Asymptomatic&#xD;
- Mild claudication&#xD;
- Moderate claudication&#xD;
- Severe claudication&#xD;
- Ischemic rest pain&#xD;
- Minor tissue loss&#xD;
- Major tissue loss</description>
          <population>Number of participants participating in the study changed at 30 Days, 12 Months and 24 Months</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="268"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Improvement of Rutherford Category of 1 or more at 30 Days</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="268"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Improvement of Rutherford Category of 1 or more at 12 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="254"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Improvement of Rutherford Category of 1 or more at 24 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="221"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Outcome (Six-Minute Walk Test)</title>
        <description>Comparison of measured at Baseline, Day 30, Months 12 and 24 (subgroup of US investigational sites only).</description>
        <time_frame>Baseline, Day 30, Months 12 &amp; 24</time_frame>
        <population>Number of participants analysed changed over the time period</population>
        <group_list>
          <group group_id="O1">
            <title>BioMimics 3D Stent</title>
            <description>Implantation of BioMimics 3D nitinol stent using the BioMimics 3D Stent System&#xD;
BioMimics 3D Stent System: Femoropopliteal stenting</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Outcome (Six-Minute Walk Test)</title>
          <description>Comparison of measured at Baseline, Day 30, Months 12 and 24 (subgroup of US investigational sites only).</description>
          <population>Number of participants analysed changed over the time period</population>
          <units>yards</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="230" spread="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Days</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="349" spread="221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="278" spread="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="405" spread="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Outcome (Ankle Brachial Index (ABI) Measurement)</title>
        <description>Comparison of the ankle brachial index (ABI) measurement at Baseline, within 30 days after index procedure, then at Months 12 and 24.</description>
        <time_frame>Baseline, Day 30, Months 12 &amp; 24</time_frame>
        <population>Number of participants assessed for ABI index measurement at Baseline, within 30 days after index procedure, then at Months 12 and 24.</population>
        <group_list>
          <group group_id="O1">
            <title>BioMimics 3D Stent</title>
            <description>Implantation of BioMimics 3D nitinol stent using the BioMimics 3D Stent System&#xD;
BioMimics 3D Stent System: Femoropopliteal stenting</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Outcome (Ankle Brachial Index (ABI) Measurement)</title>
          <description>Comparison of the ankle brachial index (ABI) measurement at Baseline, within 30 days after index procedure, then at Months 12 and 24.</description>
          <population>Number of participants assessed for ABI index measurement at Baseline, within 30 days after index procedure, then at Months 12 and 24.</population>
          <units>ABI</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ABI at Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="257"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.70" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ABI at 30 Days</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="263"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.98" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ABI at 12 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.92" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ABI at 24 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="208"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.94" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Walking Impairment Questionnaire Score</title>
        <description>Comparison of the Walking Impairment Questionnaire at Baseline, within 30 days after index procedure, then at Months 12 and 24.&#xD;
The WIQ consists of 3 primary categories assessing walking distance, stair-climbing, and walking speed, as previously described. Individuals are asked to rate the degree of difficulty of various activities with responses ranging from 0 (unable) to 4 (none).</description>
        <time_frame>Baseline, Day 30, Months 12 &amp; 24</time_frame>
        <population>Walking Impairment Questionnaire score at Baseline, within 30 days after index procedure, then at Months 12 and 24.</population>
        <group_list>
          <group group_id="O1">
            <title>BioMimics 3D Stent</title>
            <description>Implantation of BioMimics 3D nitinol stent using the BioMimics 3D Stent System&#xD;
BioMimics 3D Stent System: Femoropopliteal stenting</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Walking Impairment Questionnaire Score</title>
          <description>Comparison of the Walking Impairment Questionnaire at Baseline, within 30 days after index procedure, then at Months 12 and 24.&#xD;
The WIQ consists of 3 primary categories assessing walking distance, stair-climbing, and walking speed, as previously described. Individuals are asked to rate the degree of difficulty of various activities with responses ranging from 0 (unable) to 4 (none).</description>
          <population>Walking Impairment Questionnaire score at Baseline, within 30 days after index procedure, then at Months 12 and 24.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="270"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline WIQ score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="266"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Days WIQ score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="264"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.58" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Months WIQ score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="253"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.58" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Months WIQ score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="220"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.56" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Freedom From Stent Fracture</title>
        <description>Stent integrity measured as freedom from fracture, defined as clear interruption of a stent strut observed in a minimum of two projections, determined by core lab examination of X-rays taken with the leg in extension at 12, 24 and 36 Months.</description>
        <time_frame>Months 12, 24 &amp; 36</time_frame>
        <population>Number of participants with no fracture in study stent at 12, 24 and 36 Months assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>BioMimics 3D Stent</title>
            <description>Implantation of BioMimics 3D nitinol stent using the BioMimics 3D Stent System&#xD;
BioMimics 3D Stent System: Femoropopliteal stenting</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Freedom From Stent Fracture</title>
          <description>Stent integrity measured as freedom from fracture, defined as clear interruption of a stent strut observed in a minimum of two projections, determined by core lab examination of X-rays taken with the leg in extension at 12, 24 and 36 Months.</description>
          <population>Number of participants with no fracture in study stent at 12, 24 and 36 Months assessment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="229"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Freedom from stent fracture at 12 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="229"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Freedom from stent fracture at 24 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="204"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Freedom from stent fracture at 36 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="102"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>36 months</time_frame>
      <desc>Site reported serious adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>BioMimics 3D Stent</title>
          <description>Implantation of BioMimics 3D nitinol stent using the BioMimics 3D Stent System</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="164" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Bleeding from anticoagulant or antiplatelet medications s</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Haemorrhage, with or without transfusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Congestive heart failure (CHF)</sub_title>
                <counts group_id="E1" events="14" subjects_affected="10" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="14" subjects_affected="10" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="18" subjects_affected="13" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Myocardial ischemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Cardiac arrhythmia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Death (MAE if cardiovascular-related)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastro-intestinal bleeding</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction (medication, contrast media, device, etc.)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Infected peripheral wound</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Urinary tract infection (UTI)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arterial occlusion/thrombus at puncture site</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Vascular access complications</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Groin hematoma ≥ 5 cm, with or without surgical repair</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="172" subjects_affected="95" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Stroke or other neurological complications</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Transient ischemic attack (TIA)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure/renal insufficiency</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Restenosis of treated segment</sub_title>
                <counts group_id="E1" events="60" subjects_affected="47" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Arterial stenosis (non-target)</sub_title>
                <counts group_id="E1" events="51" subjects_affected="38" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Restenosis</sub_title>
                <counts group_id="E1" events="21" subjects_affected="14" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Restenosis of treated vessel</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Limb ischemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Dissection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Pseudoaneurysm</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Abrupt occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Amputation (unplanned, spontaneous)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Aneurysm</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Dissection (≥ Grade C) in target vessel requiring intervention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Embolization, distal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Total occlusion of the peripheral artery</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Amputation (planned)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="177" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina</sub_title>
                <counts group_id="E1" events="22" subjects_affected="18" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Vascular access complications</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial stenosis (non-target)</sub_title>
                <counts group_id="E1" events="68" subjects_affected="50" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Restenosis</sub_title>
                <counts group_id="E1" events="27" subjects_affected="18" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Restenosis of treated segment</sub_title>
                <counts group_id="E1" events="77" subjects_affected="63" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Restenosis of treated vessel</sub_title>
                <counts group_id="E1" events="18" subjects_affected="14" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nick Yeo</name_or_title>
      <organization>Veryan Medical</organization>
      <phone>+44 1403 258984</phone>
      <email>nick.yeo@veryanmed.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

